KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Common Equity: 2015-2025

Historic Common Equity for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $1.9 billion.

  • CRISPR Therapeutics AG's Common Equity fell 1.22% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 1.22%. This contributed to the annual value of $1.9 billion for FY2024, which is 2.62% up from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Common Equity is $1.9 billion, which was up 11.97% from $1.7 billion recorded in Q2 2025.
  • CRISPR Therapeutics AG's Common Equity's 5-year high stood at $2.6 billion during Q2 2021, with a 5-year trough of $1.7 billion in Q2 2025.
  • In the last 3 years, CRISPR Therapeutics AG's Common Equity had a median value of $1.9 billion in 2023 and averaged $1.9 billion.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 185.92% in 2021, then declined by 22.24% in 2022.
  • CRISPR Therapeutics AG's Common Equity (Quarterly) stood at $2.4 billion in 2021, then declined by 21.84% to $1.9 billion in 2022, then climbed by 0.39% to $1.9 billion in 2023, then rose by 2.62% to $1.9 billion in 2024, then declined by 1.22% to $1.9 billion in 2025.
  • Its Common Equity was $1.9 billion in Q3 2025, compared to $1.7 billion in Q2 2025 and $1.8 billion in Q1 2025.